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Abstract 
 
Approximately one in every 200 mammalian proteins is anchored to the cell membrane 
through a glycosylphosphatidylinositol (GPI) anchor. These proteins play important roles 
notably in neurological development and function. To date, more than 20 genes have been 
implicated in the biogenesis of GPI-anchored proteins. GPAA1 
(glycosylphosphatidylinositol anchor attachment 1 protein) is an essential component of 
the transamidase complex along with PIGK, PIGS, PIGT and PIGU (Phosphatidylinositol-
glycan biosynthesis class K, S, T and U proteins). This complex orchestrates the 
attachment of the GPI anchor to the carboxyl terminus of precursor proteins in the 
endoplasmic reticulum. Here we report bi-allelic mutations in GPAA1 in ten individuals 
from five families. Using whole exome sequencing, we identified two frameshift mutations 
(c.981_993del [p.Gln327Hisfs*102] and c.920delG [p.Gly307Alafs*11]), one intronic 
splicing mutation (c.1164+5C>T) and six missense mutations (c.152C>T [p.Ser51Leu], 
c.160_161delinsAA [p.Ala54Asn], c.527G>C [p.Trp176Ser], c.869T>C [p.Leu290Pro], 
c.872T>C [p.Leu291Pro] and c.1165G>C [p.Ala389Pro]). Most individuals presented with 
global developmental delay, hypotonia, early-onset seizures, cerebellar atrophy, and 
osteopenia. The splicing mutation was found to decrease GPAA1 mRNA. Moreover, flow 
cytometry analysis on five available individual samples showed that several GPI-anchored 
proteins had decreased cell surface abundance in leukocytes (FLAER, CD16, CD59) or 
fibroblasts (CD73, CD109). Transduction of fibroblasts with a lentivirus encoding the wild-
type protein partially rescued the GPI-anchored protein deficiency. These findings 
highlight the role of the transamidase complex in the development and function of the 
cerebellum and the skeletal system.  
Main text 
 
Initially identified more than three decades ago1, glycophosphatidylinositol (GPI) anchor 
proteins (AP) are emerging as a structurally diverse group of membrane-bound 
glycoproteins with important roles in cellular processes such as embryogenesis, 
fertilization and neurogenesis. It is estimated that there are about 150 GPI-APs in the 
human proteome.  
 
The attachment of a GPI anchor to a protein is a conserved posttranslational modification 
which occurs in the endoplasmic reticulum (ER) and requires at least twelve reactions. 
Proteins bearing the GPI-anchor exit the ER and are shuttled to the Golgi where they 
undergo fatty acid modification before being transported to the plasma membrane. Crucial 
in the GPI biosynthetic pathway are a group of enzymes encoded by five genes (PIGK 
[MIM:605087 ], PIGS [MIM: 610271], PIGT [MIM: 610272], GPAA1 [MIM: 603048], and 
PIGU [MIM: 608528]) forming the GPI transamidase complex. These proteins mediate 
coupling of the synthesized GPI-anchor to mature proteins with a carboxyl terminal GPI-
attachment signal peptide2 in two principal steps; the cleavage of a C-terminal propeptide 
from the substrate protein and the formation of an amide bond between the C-terminal 
UHVLGXHȦ-site) of the substrate protein and a phosphoethanolamine group of the GPI lipid 
anchor2. Among the five known subunits of the GPI lipid anchor transamidase complex, 
GPAA1 was the first to be discovered3; 4 but its physiological role was only demonstrated 
recently5. This protein is composed of an N-terminal transmembrane domain, a luminal 
region and a hydrophobic region containing six transmembrane domains in the C-
terminus. Recently, Eisenhaber et al. demonstrated that the luminal region of GPAA1 is 
similar to M28-type peptidases and that it may have one Zn-binding site like some of the 
M28 family peptidases. This protein was thus suggested to be a catalyst in the second 
step to complete the transamidation5. Several inherited disorders are known to be caused 
by GPI biosynthesis defects6. However, mutations in GPAA1 have yet to be reported in 
diseases other than cancer7-10. Here, we present functional characterization of GPAA1 
mutations in ten individuals with GPAA1 deficiency who manifest clinical features 
consistent with other inherited GPI-anchor deficiencies, including developmental delay, 
hypotonia and seizures. 
 
Ten individuals from five unrelated families with bi-allelic GPAA1 (Gene bank: 
NM_003801.3) mutations were included in this study. Individuals were identified by a 
search in the Baylor Genetics Laboratory proband whole exome sequencing database, 
the DECIPHER database11, Genematcher12, and contacting collaborators. Informed 
consent was obtained from all families according to protocols approved by the Institutional 
Review Board at the relevant institutions. Most individuals had global developmental delay 
including late or absent independent walking and speech abilities. Among the more 
severely affected individuals, six individuals from families 1, 2, 3 and 5 are unable to walk 
independently at age 6 and up, and the individual from family 2 has not acquired speech 
as of age 6. Hypotonia was identified in all cases at an early age. Seizures were present 
in seven individuals; cerebellar atrophy was found in seven individuals (see MRI in figure 
1B) and osteopenia also in five individuals. Further clinical features are summarized in 
table 1, table S1, and additional MRI images of family 4 can be found in figures S1 to S4.  
 
Exome sequencing showed compound heterozygous mutations in the two siblings of 
family 1 (Hispanic origin from the USA), a missense mutation c.872T>C [p.Leu291Pro] 
inherited from the father and a frameshift mutation c.981_993del [p.Gln327Hisfs*102] 
which is from the mother (Figure 1). Individual 2 (II-2 of family 2 in figure 1, a white family, 
from the USA) has a missense mutation c.152C>T [p.Ser51Leu] from the mother and an 
intronic splicing mutation c.1164+5C>T from the father. He has an unaffected sibling who 
carries only the c.152C>T [p.Ser51Leu] mutation but no splicing mutation. Two affected 
siblings from an Egyptian-origin family (family 3) have a frameshift mutation c.920delG 
[p.Gly307Alafs*11] and missense mutation c.1165G>C [p.Ala389Pro]. A homozygous 
missense mutation c.527G>C [p.Trp176Ser] was found in two Pakistani siblings from 
family 4 and a distant cousin, all of whose parents are consanguineous. Two affected 
siblings from family 5 (a Finnish family) had compound heterozygous mutations, a 
missense mutation c.869T>C [p.Leu290Pro] inherited from the father and a missense 
mutation c.160_161delinsAA [p.Ala54Asn] inherited from the mother. DNA from two 
unaffected siblings was not available for sequencing. These mutations were either not 
seen in ExAC or noted at very low frequency without homozygotes (Table 2). See figure 
1 for the pedigrees and figure 2 for the location of the mutations and the conservation of 
the substituted amino acids. 
  
Frameshift or splicing mutations that introduce premature stop codons before the last 50 
nucleotides of the penultimate exon usually trigger nonsense-mediated mRNA decay 
(NMD). To determine if the mutations identified in our cohort triggered NMD, we performed 
real-time PCR on both fibroblasts and lymphoblastoid cell lines (LCLs) of individuals 1a 
and 1b (II-1 and II-2 of family 1 in figure 1) with the frameshift mutation (c.981_993del) 
which introduces a stop codon at amino acid 428 (p.Gln327Hisfs*102). We observed a 
decrease in GPAA1 mRNA up to 50% in both fibroblasts and LCLs (Figure 3A, B).  
Similarly, individual 2 (II-2 of family 2 in figure 1) with the intronic splicing mutation 
c.1164+5C>T also has decreased mRNA expression of GPAA1 in LCLs (Figure 3B). 
 
To assess whether these mutations could affect the level of GPI-AP found at the cell 
surface, we performed flow cytometry analysis on whole blood and LCLs of affected 
individuals from families 1, 2  and 4 (samples from families 3 and 5 were not available). 
Our results show that all tested individuals have GPI-AP deficiency. As shown in Figure 
3C, individuals 1a and 1b (II-1 and II-2 of family 1 in figure 1) and 2 (II-2 of family 2 in 
figure 1) from two families presented with lower level of total GPI-AP in granulocytes as 
measured by a decrease in fluorescence-labeled aerolysin (FLAER) staining, while lower 
levels of CD16 were observed only in individuals 2 (II-2 of family 2 in figure 1), 4a and 4b 
(VII-1 and VII-2 of family 4 in figure 1).  In all LCLs examined, cell surface staining also 
showed decreased FLAER abundance (Figure 3D). In addition, a moderate decrease in 
CD24 was observed in all individual cell lines (Figure S5).  
 
Since fresh blood samples were not available for the affected individuals in family 3, we 
also tested the effect of the mutations by transfecting plasmids encoding mutant cDNAs 
driven by a weak promoter with only TATA box in cells knocked-out for GPAA1. GPAA1-
deficient HAP1 cells were generated by CRISPR-Cas9 targeting of the gene.  We then 
cloned human GPAA1 isoform 1 from a Hep3B cDNA library, and ligated to generate C-
terminal tagged wild-type and variant pME hGPAA1 HA, then generated by site-directed 
muWDJHQHVLVWKHGLIIHUHQWYDULDQWV7KHS0(SURPRWHULVWKH65ĮSURPRWHU69HDUO\
promoter + HTLV LTR, enhancer)13. We also subcloned the constructs in plasmids with 
an intermediate strength promoter (pTK using the herpes simplex virus thymidine kinase, 
or HSV-TK, promoter), and a weak promoter (pTA using the TATA box from the HSV-TK 
promoter).  The pTA promoter activity is similar to that of a promoter-less plasmid. The 
promoter activities are estimated as pTA:pTK:pME = 1:60:6000. 
These results show a decreased activity compared to the wild-type protein only for the 
p.Ser51Leu and the p.Ala389Pro variants (Figure 4A). In this overexpression experiment, 
the other variants (p.Trp176Ser and p.Leu291Pro) possibly have sufficient residual 
activities to provide a rescue. Similar results were obtained after transfection with plasmids 
encoding the cDNAs under the control of stronger promoters (see Figures S6 and S7). 
Western blotting of cell lysates after transfection of cells with a strong promoter (pME) 
indicates that the p.Ala389Pro variant, located in the second transmembrane domain, 
leads to protein instability (Figure 4B). This could possibly be due to inadequate 
incorporation of the protein into the ER membrane. 
 
We also assessed GPI-AP abundance on the cell surface of skin fibroblasts derived from 
individuals 1a, 1b (II-1 and II-2 of family 1 in figure 1) and 2 (II-2 of family 2 in figure 1) 
using FLAER, CD73 and CD109 as GPI cell surface markers (Figure S8). Since individuals 
1a and individual 2 had a significant downregulation in CD109 and CD73, respectively, we 
carried out rescue assays of these GPI-APs on fibroblasts of these individuals using a 
GPAA1-encoding Lv105 lentiviral vector. As shown in Figure 5, CD109 in individual 1a 
fibroblasts was completely rescued, and a partial rescue of CD73 was observed in 
individual 2 fibroblasts. Collectively, these findings demonstrate that individuals with 
GPAA1 mutations have GPI-AP deficiency, which likely causes their clinical 
manifestations. The protein with the p.Trp176Ser variant might cause a milder biochemical 
effect since when overexpressed, no decreased activity was noted. 
 
There is clinical overlap between these individuals and those with other GPI biosynthesis 
defects. Inherited mutations in PIGA [MIM: 311770]14-16, PIGM [MIM: 610273]17, PIGL 
[MIM: 605947]18, PIGW [MIM: 610275]19, PIGV [MIM: 610274]20; 21, PIGO [MIM: 610274]22; 
23
, PIGN [MIM: 606097]24, PIGC [MIM: 601730]25, PIGP [MIM: 605938]26 and PIGG [MIM: 
616918]27 were identified as causing GPI-biosynthesis disorders. Similar disorders can 
also be caused by mutations in PGAP genes (Post GPI Attachment to Proteins, notably 
PGAP1 [MIM: 611655]28, PGAP2 [MIM: 615187]29; 30 and PGAP3 [MIM: 611801]31), which 
code for a family of proteins involved in structural remodeling of the GPI anchor after its 
attachment to proteins. The phenotypes of the individuals with GPAA1 mutations in the 
present study overlap with those identified in other GPI-biosynthesis disorders, such as 
the epilepsy, hypotonia and developmental delay23; 32; 33, as well as the progressive 
cerebellar atrophy in individuals with PIGT and PIGN mutations24; 34. The rate and severity 
of the progressive atrophy is comparable to that seen with PIGT and PIGN deficiency, 
although the finding is is rarer in PIGN deficiency. The only reported GPI-transamidase 
complex gene associated with GPI deficiency is PIGT, which causes 
multiple congenital anomalies-hypotonia-seizures syndrome4; 32; 33; 35, characterized by 
hypotonia, developmental delay, seizures, dysmorphisms, and malformations of the heart, 
urinary tract and gastrointestinal system. With relevance to the condition we describe here, 
most of these individuals also have osteopenia.  
 
All the individuals we describe have normal plasma and/or serum alkaline phosphatase 
(ALP) levels (Table 1), which can be perturbed in other GPI-AP-synthesis-related 
disorders. Previous data suggested that the elevated serum ALP observed in some GPI-
biosynthesis defects could be explained by cleavage of the signal peptide and secretion 
of soluble ALP because of abnormal GPI structure.36 Since GPAA1 is a component of the 
GPI transamidase complex, mutations in this gene leading to decreased activity might 
lead to a decrease in serum ALP. This was not observed in our cohort, perhaps because 
the remaining enzymatic activity is sufficient to maintain normal serum ALP. This 
hypothesis is supported by the fact that no individual with bi-allelic loss-of-function 
mutations was identified. With regards to the mechanism leading to osteopenia, perhaps 
decreased surface expression of ALP on osteoblasts affects its function and secondarily 
leads to the osteopenia seen in these individuals.  
 
To date, GPI-transamidase subunits have been proposed to function as oncogenes in 
breast and bladder cancer7-9. In addition, GPAA1 mRNA was also found to be 
overexpressed, correlating with increased GPAA1 protein accumulation, in samples from 
individuals with colorectal cancer10. It is thought that an overexpression of GPI-
biosynthesis genes might lead to increased uPAR (a GPI-anchored protein) which in turn 
can lead to increased invasiveness and growth of tumor cells37.  
 
Limited therapies are available for GPI-AP deficiency. Since alkaline phosphatase is 
essential to allow pyridoxal-phosphate to pass through the blood-brain barrier and 
pyridoxine passes through the blood-brain barrier and is converted to pyridoxal-
phosphate, which is important for GABA synthesis, pyridoxine supplementation 
sometimes helps control the seizures in individuals with GPI-biosynthesis defects 
including some patients with PIGO and PIGV mutations38; 39. This potential treatment has 
not yet been tested in our cohort. Future studies of GPAA1 deficiency, such as in mouse 
models, could allow further pathophysiological studies to explore the cerebellar and bone 
manifestations, and explore therapeutic avenues. 
 
In summary, we report biallelic mutations in GPAA1 in ten individuals presenting global 
developmental delay, hypotonia, early-onset seizurescerebellar atrophy., and osteopenia. 
Moreover, with functional studies, we demonstrate that these individuals have low cell 
surface GPI-AP levels demonstrating that those mutations cause a defect in the 
biosynthesis of GPI anchored proteins. Thus, our work expands the group of GPI-
biosynthesis disorders and contributes to the understanding of the role of the GPI 
transamidase complex in health and development. 
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Supplemental Data include supplemental text, one table, eight figures and can be found 
with this article online. 
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Figure titles and legends 
Figure 1. A) Pedigrees of five families with GPAA1 mutations in the study. B) MRI of 
individual 4b (VII-2 of family 4) at 25 months. T1 sagittal image shows marked reduction 
in cerebellar volume (arrow). C) Photographs of, starting from the top right, individuals 1a 
(age 15), 1b (age 10), 3a (age 10), 3b (age 3), and 5 (age 25). A slightly broad and 
prominent root of the nose is noted in individuals 1b, 3b and 5. 
Figure 2. A) Location of the protein variants on the GPAA1 protein (for the splicing 
mutation, the site of the exon-exon junction is shown). B) Amino acid conservation in 
vertebrates of the amino acids affected by substitution mutations. 
Figure 3. GPAA1 expression by Real time-PCR in individuals from families 1 and 2. RNA 
extractions from fibroblasts (A) and LCLs (B) of individuals 1a, 1b and 2 were subjected 
to qRT-PCR. Figures show the results normalized to a reference gene (TBP for fibroblast 
and GAPDH  for LCLs) from quadruplicate experiments. C) GPI-AP abundance in 
granulocytes of individuals from familly 1, 2 and 4. Fresh blood samples as well as healthy 
controls were fixed with 10% formaldehyde, red blood cells were lysed in 0.1% Triton X-
100 and the samples were stained with GPI-AP markers (FLAER, CD16) for 1 hour at 
room temperature. Non-specific binding was washed before analyzing by BD FACScanto 
II system. The figure shows representative results from experiments done in triplicate. D) 
GPI-AP abundance in LCLs of individuals from familly 1, 2 and 4. LCLs were established 
by Epstein-Barr virus immortalization of peripheral blood mononuclear cells (PMBC). Cells 
were stained with a GPI-AP marker (FLAER) for 1 hour at room temperature. Non-specific 
binding was washed before analysing the cell surface abundance of GPI-APs by BD 
FACScanto II system. The figure shows representative results from experiments done in 
triplicate. 
Figure 4. A) Rescue of GPAA1 knockout cells. GPAA1-knockout cells were transiently 
transfected with a plasmid encoding wild-type or variant GPAA1 under the control of a 
weak promoter (pTA plasmid) by electroporation. Transfection efficiency was monitored 
by luciferase assay, and flow cytometry analysis was performed 2 days after transfection. 
These results show a slightly decreased labelling only  for the p.Ser51Leu and the 
p.Ala389Pro variants (fewer cells with a strong signal), possibly because the residual 
activities for the other variants are sufficient to provide a rescue in this experiment. B) The 
p.Ala389Pro variant leads to protein instability. HEK293 cells were transiently transfected 
with various GPAA1 cDNAs and proteins were analyzed by Western Blotting using an anti-
HA antibody (Cell Signaling). Intensities of the bands were normalized with the loading 
control (GAPDH), and luciferase activities used for evaluating transfection efficiencies. 
Western blot for the tagged protein indicates that p.Ala389Pro, in the second 
transmembrane domain, leads to protein instability. 
Figure 5. Lentivirus rescue assays in fibroblasts from individuals 1a and 2. Skin fibroblasts 
derived from individuals 1a and 2 were transduced with GPAA1-expressing-Lv105 
lentivirus or empty vector-lentivirus, then transduced, and non-transduced cells were 
stained with CD109 and CD73 for 1 hour at room temperature. The non-specific binding 
was washed before analysing the cell surface abundance of GPI-APs by BD FACScanto 
II system. The figure shows representative results from experiments done in triplicate. 
 
Tables  1 
Table 1. Key clinical features. More details can be found in the supplement. 2 
Individual 1a 1b 2 3a 3b 4a 4b 4c 5a 5b 
  Gender F M M F F F M F M M 
Age at last 
assessment 
(yr) 
15 10 6y 10.7 3.8 8 5 4 30 25 
Height, cm 152.4 
(8th %ile) 
127 
(4th 
%ile) 
103.2 
(59th %ile) 
at 4 y 
125 (1st 
%ile, -2.3 
SD) 
95 (15th 
%ile) 
109 (1st 
%ile, -3.3 
SD) 
98 (1st 
%ile, -2.3 
SD) 
93 (1st 
%ile -2.2 
SD) 
165 (± 2 
SD) 
167 (± 
1.8 SD) 
Weight, kg  54.4 
(58th 
%ile) 
27.8 
(16th 
%ile) 
15.4 (30th 
%ile) 
35 (49th 
%ile) 
14 (19th 
%ile) 
23.6 (27th 
%ile) 
17 (23rd 
%ile) 
15 (31st  
%ile) 
70 
(48th%ile) 
62.4 
(31st 
%ile) 
OFC, cm 53 (14th 
%ile) 
52 
(27th 
%ile) 
52 (87th 
%ile) 
49.5 (1st 
%ile, -2.3 
SD) 
48 (19th 
%ile) 
51 (31st 
%ile) 
48.6 (4th 
%ile) 
48 (18th 
%ile) 
57,2 (50th 
%ile) 
57,2 
(50th 
%ile) 
Developmen
tal delay/ 
Intellectual 
disabilitya 
++ ++ ++ ++ ++ ++ ++ + ++ ++ 
Hypotonia + + + + + + + ++ + + 
Seizures GTC, 
myocloni
c, atonic 
GTC GTC GTC GTC, 
myoclon
ic 
No No No GTC, 
myoclonic, 
atonic, 
absence 
GTC, 
myoclon
ic 
Cerebellar 
atrophy 
+ + - at age 1 + + + + + + + 
Nystagmus + + - but 
cortical 
visual 
impairme
nt 
+ + + - ++ + + 
Dysarthria NA + NA + NA NA NA + + + 
Dysmetria + + NA NA NA NA + + + + 
Ataxic gait + + NA NA NA + + ++ + + 
Spasticity 
 
 
 
- - - + NA + + + - - 
Osteopenia + + + + (Z=-
2.2) 
+ (Z=-
2.0) 
+ + + NA NA 
Dysmorphis
ms 
None Slightl
y 
broad 
root of 
the 
nose 
Bitempora
l 
narrowing 
with 
prominent 
forehead, 
anterevet
ed nares 
Bitempor
al 
narrowin
g, widely 
spaced 
eyes, 
prominen
t ears 
Slightly 
broad 
root of 
the nose 
Bitempora
l 
narrowing
, 
prominent 
forehead, 
anterevet
ed nares,  
Bitempora
l 
narrowing
, 
prominent 
forehead, 
anterevet
ed nares 
Narrow 
promine
nt 
forehead 
antevert
ed nares 
None Slightly 
broad 
root of 
the nose 
Plasma 
alkaline 
phosphatase 
(U/L) 
155 (Nl) 143 
(Nl) 
223 (Nl) 355 (Nl) 624 (Nl) 176 (Nl) 183 (Nl) 201 (Nl) Serum 
alkaline 
phosphata
se 465 
(275-875 
U/L)(NI) 
180 (NI) 
aLegend: For the intellectual disability, + refers to mild, ++ to moderate, +++ to severe.; NA, not available; Nl, normal; GTC, 3 
generalized tonic-clonic seizure; OFC, occipitofrontal circumference; F, female; M, male; %ile, percentile; SD, standard deviation 4 
from the mean. 5 
 6 
  7 
Table 2. Genetic description of the GPAA1 variants. 8 
Family
  
Genomic variant 
(hg19) 
cDNA variant 
(NM_003801.3) 
Protein variant Inheritance ExAC minor allele frequency 
1 chr8:g.145139374T>C c.872T>C p.Leu291Pro Compound 
heterozygous 
Not present 
chr8:g.145139483_145
139495del 
c.981_993del p.Gln327Hisfs*102 Compound 
heterozygous 
Not present 
2 chr8:g.145138104C>T c.152C>T p.Ser51Leu Compound 
heterozygous 
Not present 
chr8:g.145139783C>T c.1164+5C>T Splicing Compound 
heterozygous 
1.661e-05 total, 0.0001226 in 
South Asians. No homozygotes 
detected.  
3 chr8:g.145139422del c.920delG p.Gly307Alafs*11 Compound 
heterozygous 
Not present 
chr8:g.145139946 
G>C 
c.1165G>C p.Ala389Pro Compound 
heterozygous 
8.681e-06 total, 7.592e-05 in 
South Asians. No homozygotes 
detected. 
4 chr8:g.145138854G>C c.527G>C p.Trp176Ser Homozygous 1.658e-05 total, 0.0001211 in 
South Asians. No homozygotes 
detected. 
5 chr8:g.145138112_145
138113delinsAA 
c.160_161delinsAA p.Ala54Asn Compound 
heterozygous 
Not present 
 chr8:g.145139371T>C c.869T>C p.Leu290Pro Compound 
heterozygous 
Not present 
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